Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...
Some studies show that intermittent fasting may help maintain a healthy metabolism. When the body is in a fasted state, it ...
Hosted on MSN2h
After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
Asian stocks are mixed after Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...
Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...
6h
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...
Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback